AR081992A2 - FORMA POLIMORFICA g DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS - Google Patents

FORMA POLIMORFICA g DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS

Info

Publication number
AR081992A2
AR081992A2 ARP110102194A ARP110102194A AR081992A2 AR 081992 A2 AR081992 A2 AR 081992A2 AR P110102194 A ARP110102194 A AR P110102194A AR P110102194 A ARP110102194 A AR P110102194A AR 081992 A2 AR081992 A2 AR 081992A2
Authority
AR
Argentina
Prior art keywords
rifaximin
crystallization
production
carried out
water content
Prior art date
Application number
ARP110102194A
Other languages
English (en)
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33187382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR081992(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of AR081992A2 publication Critical patent/AR081992A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1236—Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1245—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
    • H05B6/1263—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe una forma pobremente cristalina del antibiótico rifaximina (INN), denominada rifaximina g que presenta un contenido de agua entre 1,0% y 2,0% y produce un difractograma de polvo por rayos X que presenta un perfil fundamentalmente amorfo y pocos picos significativos en valores de ángulos de difracción 2q de 5,0º; 7,1º, 8,4º. Esta forma es de utilidad en la producción de preparaciones medicinales para uso por vía oral y tópica y se pueden obtener por medio de un proceso de cristalización llevado a cabo por disolución en caliente de la rifaximina cruda en alcohol etílico y por cristalización del producto mediante la adición de agua a una temperatura determinada y por un período de tiempo determinado. La cristalización es seguida de un secado llevado a cabo bajo condiciones controladas hasta alcanzar un contenido de agua específico en el producto final.
ARP110102194A 2003-11-07 2011-06-23 FORMA POLIMORFICA g DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS AR081992A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002144A ITMI20032144A1 (it) 2003-11-07 2003-11-07 Forme polimorfe di rifaximina, processi per ottenerle e

Publications (1)

Publication Number Publication Date
AR081992A2 true AR081992A2 (es) 2012-10-31

Family

ID=33187382

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP040100781A AR043547A1 (es) 2003-11-07 2004-03-11 Formas polimorficas de rifaximina, procesos para su produccion y uso de las mismas en preparaciones medicinales
ARP110102194A AR081992A2 (es) 2003-11-07 2011-06-23 FORMA POLIMORFICA g DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS
ARP110102193A AR081991A2 (es) 2003-11-07 2011-06-23 FORMA POLIMORFICA b DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP040100781A AR043547A1 (es) 2003-11-07 2004-03-11 Formas polimorficas de rifaximina, procesos para su produccion y uso de las mismas en preparaciones medicinales

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP110102193A AR081991A2 (es) 2003-11-07 2011-06-23 FORMA POLIMORFICA b DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS

Country Status (37)

Country Link
US (5) US7045620B2 (es)
EP (6) EP1676848B1 (es)
JP (5) JP2005139161A (es)
KR (4) KR20050043589A (es)
CN (4) CN1613858A (es)
AR (3) AR043547A1 (es)
AT (3) ATE421966T1 (es)
AU (2) AU2004200964A1 (es)
BR (2) BRPI0402382A (es)
CA (2) CA2460384A1 (es)
CL (1) CL2004000498A1 (es)
CO (1) CO5560083A1 (es)
CY (3) CY1108017T1 (es)
DE (4) DE602004019296D1 (es)
DK (3) DK1557421T3 (es)
ES (3) ES2320160T4 (es)
HR (2) HRP20040265A2 (es)
IL (2) IL160798A0 (es)
IT (1) ITMI20032144A1 (es)
JO (1) JO2470B1 (es)
MA (1) MA27069A1 (es)
MD (1) MD3653G8 (es)
ME (1) ME00424B (es)
MX (2) MXPA04002353A (es)
NO (1) NO334950B1 (es)
NZ (1) NZ531622A (es)
PL (3) PL1676848T3 (es)
PT (3) PT1557421E (es)
RS (4) RS54569B1 (es)
RU (1) RU2270200C2 (es)
SI (3) SI1676848T1 (es)
TN (2) TNSN04044A1 (es)
TW (1) TWI285107B (es)
UA (1) UA86384C2 (es)
WO (1) WO2005044823A2 (es)
YU (1) YU24804A (es)
ZA (1) ZA200401948B (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
PT1698630E (pt) * 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
SI2054066T1 (sl) 2006-08-02 2015-08-31 Salix Pharmaceuticals, Inc. Postopki za zdravljenje radiacijskega enteritisa
ITMI20061692A1 (it) * 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
WO2008035109A1 (en) * 2006-09-22 2008-03-27 Cipla Limited Rifaximin
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
PL2011486T5 (pl) * 2007-07-06 2016-09-30 Lupin Ltd Farmaceutyczne kompozycje rifaksyminy
WO2009008005A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
GEP20135898B (en) * 2008-02-25 2013-08-12 Salix Pharmaceuticals Ltd Rifaximin forms and usage
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
BRPI0908026B8 (pt) * 2008-02-26 2021-05-25 Salix Pharmaceuticals Ltd uso de rifaximina no tratamento de doenças do intestino
US11779571B2 (en) * 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
US20110065741A1 (en) 2009-02-26 2011-03-17 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs)
WO2009137672A1 (en) 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
KR20110071096A (ko) 2008-09-26 2011-06-28 아스카 세이야쿠 가부시키가이샤 기능성 소화관 장해의 예방 및/또는 치료제
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
HRP20200284T1 (hr) 2008-10-02 2020-07-10 Salix Pharmaceuticals, Ltd. Postupci liječenja hepatičke encefalopatije
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20100317681A1 (en) * 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
KR101906177B1 (ko) 2008-12-10 2018-10-10 시플라 리미티드 리팍시민 복합체
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
CN102548408A (zh) * 2009-06-02 2012-07-04 萨利克斯药品有限公司 治疗肝性脑病的方法
GEP201706693B (en) * 2009-10-27 2017-07-10 Lupin Ltd Solid dispersion of rifaximin
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
CA2781580A1 (en) 2009-11-23 2011-05-26 Cipla Limited Topical foam composition
EP2401282B2 (en) † 2009-12-28 2017-01-04 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
AU2011218129A1 (en) 2010-02-18 2012-08-23 Board Of Regents Of The University Of Texas System Methods for treating infection
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
MX2012013945A (es) * 2010-06-03 2013-05-06 Salix Pharmaceuticals Ltd Nuevas formas de rifaximina y usos de las mismas.
CA2802874A1 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
PH12013500082B1 (en) * 2010-07-12 2019-06-28 Salix Pharmaceuticals Ltd Formulations of rifaximin and uses thereof
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) * 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
MX350448B (es) 2011-02-11 2017-09-07 Salix Pharmaceuticals Ltd Formas de rifaximina y usos de las mismas.
EP2705042A1 (en) 2011-05-02 2014-03-12 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
EP2773205B1 (en) * 2011-11-02 2024-05-22 Salix Pharmaceuticals, Inc. Rifaximin for retreating diarrhea-predominant irritable bowel syndrome
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
CA2876737A1 (en) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9849090B2 (en) 2012-12-12 2017-12-26 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of rifaximin
CA2897758A1 (en) 2013-03-15 2014-09-18 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections
EP2971062A2 (en) 2013-03-15 2016-01-20 ALFA WASSERMANN S.p.A. Method for diagnosing vaginal infections
EA032705B1 (ru) 2013-04-12 2019-07-31 Альфасигма С.П.А. Способ лечения или предупреждения энтеропатии
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
ES2621557T3 (es) * 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
EP3134415A4 (en) 2014-04-19 2017-10-25 Granules India Limited An improved process for the preparation of rifamycin derivatives
WO2015171493A1 (en) 2014-05-04 2015-11-12 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
DK3546464T3 (da) 2014-05-12 2020-07-27 Alfasigma Spa Fremstilling og anvendelse af den krystallinske form tau af rifaximin solvateret med degme
WO2016003536A1 (en) * 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Methods for retreating irritable bowel syndrome (ibs)
CN104083324B (zh) * 2014-07-10 2017-05-10 青岛动保国家工程技术研究中心有限公司 一种利福昔明的兽用悬乳剂及其制备方法和应用
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
CN104274391B (zh) * 2014-10-08 2017-02-01 哈尔滨坤盟医药科技有限公司 一种含利福昔明的药物制剂
WO2017021975A1 (en) * 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
EP3536311B1 (en) 2016-03-24 2021-12-22 Sandoz AG Storage stable composition comprising rifaximin alpha
TR201816080T4 (tr) 2016-03-24 2018-11-21 Sandoz Ag Ri̇faksi̇mi̇n alfa & delta i̇çeren farmasöti̇k bi̇leşi̇m
US9988398B2 (en) * 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
JP7027412B2 (ja) 2016-09-30 2022-03-01 サリックス ファーマスーティカルズ，インコーポレーテッド リファキシミンの固体分散体の形態
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
EP3416627B9 (en) 2017-04-26 2020-04-22 Sandoz AG Oral dosage form comprising rifaximin in form beta
HUE054832T2 (hu) 2017-06-26 2021-10-28 Biofer Spa Pirido-imidazo rifamicinszármazékok baktériumellenes szerként
EP3902528A1 (en) * 2018-12-19 2021-11-03 Friulchem SpA Process for the manufacture of a tablet of rifaximin and tablet of rifaximin
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
BR112022003500A2 (pt) 2019-09-24 2022-05-24 Bausch Health Ireland Ltd Formulações líquidas de rifaximina
US20230116647A1 (en) 2020-03-24 2023-04-13 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
WO2021229480A1 (en) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin
JP7825575B2 (ja) 2020-06-26 2026-03-06 バウシュ ヘルス アイルランド リミテッド 標的化放出リファキシミン組成物
US20230398102A1 (en) 2020-10-29 2023-12-14 Bausch Health Ireland Limited Rifaximin liquid formulations for use inthe treatment of sickle cell disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241785A (en) * 1978-07-24 1980-12-30 Peerless Of America, Inc. Heat exchangers and method of making same
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
DE69111607T2 (de) * 1990-06-29 1995-12-21 Lepetit Spa Reine kristalline form von rifapentin.
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
AU2002212340B2 (en) * 2000-10-31 2006-12-14 Sandoz Ag Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050262269A1 (en) 2004-05-20 2005-11-24 Pike Jimmy D System and method for information handling system PCI express advanced switching
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
WO2008035109A1 (en) * 2006-09-22 2008-03-27 Cipla Limited Rifaximin
WO2008115572A1 (en) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Methods and compositions of nsaids
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
PL2011486T5 (pl) 2007-07-06 2016-09-30 Lupin Ltd Farmaceutyczne kompozycje rifaksyminy
WO2009008005A1 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
GEP20135898B (en) 2008-02-25 2013-08-12 Salix Pharmaceuticals Ltd Rifaximin forms and usage

Also Published As

Publication number Publication date
EP1676847A1 (en) 2006-07-05
RS20150292A1 (sr) 2015-10-30
AU2004287601B2 (en) 2009-02-26
DK1676848T3 (da) 2009-05-11
BRPI0407149A (pt) 2006-02-07
US20120059023A1 (en) 2012-03-08
KR20060110737A (ko) 2006-10-25
HRP20060093A2 (en) 2006-05-31
US20110160449A1 (en) 2011-06-30
IL174271A (en) 2010-12-30
TNSN06069A1 (en) 2007-10-03
AR081991A2 (es) 2012-10-31
DE602004019298D1 (de) 2009-03-19
IL160798A0 (en) 2004-08-31
AU2004287601A1 (en) 2005-05-19
CN101260114A (zh) 2008-09-10
US20080132530A1 (en) 2008-06-05
KR20070113326A (ko) 2007-11-28
RS54568B1 (sr) 2016-06-30
CY1108964T1 (el) 2014-07-02
CN101260114B (zh) 2012-11-28
US8173801B2 (en) 2012-05-08
HRP20060093B1 (hr) 2015-12-18
RU2270200C2 (ru) 2006-02-20
KR20070113327A (ko) 2007-11-28
AR043547A1 (es) 2005-08-03
EP2208730A1 (en) 2010-07-21
ES2320160T3 (es) 2009-05-19
HRP20040265A2 (en) 2004-12-31
RS20060168A (sr) 2008-09-29
RS54571B1 (sr) 2016-06-30
SI1676848T1 (sl) 2009-06-30
ATE361927T1 (de) 2007-06-15
ATE421965T1 (de) 2009-02-15
DE602004006367D1 (de) 2007-06-21
HK1073657A1 (en) 2005-10-14
IL174271A0 (en) 2006-08-01
TNSN04044A1 (en) 2006-06-01
US20050101598A1 (en) 2005-05-12
MXPA06002644A (es) 2006-06-06
DE602004019296D1 (de) 2009-03-19
EP1557421A1 (en) 2005-07-27
CA2538546C (en) 2011-04-19
JP5635376B2 (ja) 2014-12-03
AU2004287601B8 (en) 2009-03-05
EP1676848A1 (en) 2006-07-05
CY1108017T1 (el) 2013-09-04
EP1682556A2 (en) 2006-07-26
US7915275B2 (en) 2011-03-29
MA27069A1 (fr) 2004-12-20
DK1557421T3 (da) 2007-09-17
ES2320160T4 (es) 2011-03-09
MD20060080A (en) 2006-11-30
SI1676847T1 (sl) 2009-06-30
MD3653F2 (en) 2008-07-31
CL2004000498A1 (es) 2005-03-11
ITMI20032144A1 (it) 2005-05-08
NO334950B1 (no) 2014-08-04
MD3653G8 (ro) 2016-08-31
NZ531622A (en) 2004-10-29
JP2014177500A (ja) 2014-09-25
JP2011046738A (ja) 2011-03-10
AU2004200964A1 (en) 2005-05-26
DE04005541T1 (de) 2005-12-29
CN101260115B (zh) 2011-11-23
CA2460384A1 (en) 2005-05-07
PL1676847T3 (pl) 2009-07-31
JO2470B1 (en) 2009-01-20
CY1108909T1 (el) 2014-07-02
DE602004006367C5 (de) 2019-04-04
CN1613858A (zh) 2005-05-11
JP2011057698A (ja) 2011-03-24
TW200515913A (en) 2005-05-16
HK1092151A1 (en) 2007-02-02
YU24804A (sh) 2006-08-17
JP5199576B2 (ja) 2013-05-15
EP2210893A1 (en) 2010-07-28
ES2320161T3 (es) 2009-05-19
ME00424B (me) 2011-10-10
SI1557421T1 (sl) 2007-08-31
DE602004006367T2 (de) 2007-09-06
ES2244364T3 (es) 2007-12-01
EP1676848B1 (en) 2009-01-28
US8404704B2 (en) 2013-03-26
ES2244364T1 (es) 2005-12-16
HK1092150A1 (en) 2007-02-02
KR100855084B1 (ko) 2008-08-29
CN101260115A (zh) 2008-09-10
CN1886408B (zh) 2010-06-09
KR20050043589A (ko) 2005-05-11
CA2538546A1 (en) 2005-05-19
BRPI0402382A (pt) 2005-06-28
JP2005139161A (ja) 2005-06-02
KR100867751B1 (ko) 2008-11-10
RS54569B1 (sr) 2016-06-30
WO2005044823A2 (en) 2005-05-19
TWI285107B (en) 2007-08-11
EP1676847B1 (en) 2009-01-28
KR100883216B1 (ko) 2009-02-13
PT1676847E (pt) 2009-04-09
US20050272754A1 (en) 2005-12-08
NO20061110L (no) 2006-04-19
RU2004108953A (ru) 2005-10-27
CO5560083A1 (es) 2005-09-30
PT1676848E (pt) 2009-04-09
PT1557421E (pt) 2007-07-31
CN1886408A (zh) 2006-12-27
BRPI0407149A8 (pt) 2019-01-15
RS20150291A1 (sr) 2015-10-30
UA86384C2 (uk) 2009-04-27
JP2007509904A (ja) 2007-04-19
ATE421966T1 (de) 2009-02-15
PL1676848T3 (pl) 2009-07-31
WO2005044823A3 (en) 2005-10-27
ZA200401948B (en) 2004-04-29
MXPA04002353A (es) 2005-05-11
DK1676847T3 (da) 2009-05-11
US7045620B2 (en) 2006-05-16
EP1557421B1 (en) 2007-05-09
PL1557421T3 (pl) 2007-08-31

Similar Documents

Publication Publication Date Title
AR081992A2 (es) FORMA POLIMORFICA g DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS
EP1698630A8 (en) New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
WO2011048604A3 (en) Processes for the preparation of darunavir and the amorphous form thereof
FR2923482B1 (fr) Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
EP2184354A4 (en) ISOPROPYL ALCOHOL-PRODUCING BACTERIUM AND METHOD FOR THE PRODUCTION OF ISOPROPYL ALCOHOL USED THEREOF
IL175860A0 (en) Method for the production of a solid, orally applicable pharmaceutical composition
ECSP066914A (es) FORMA CRISTALINA dd DEL CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
EP2641897A3 (en) A process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and synthetic intermediates thereof
AR062397A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de fibrosis
IL177173A0 (en) New crystalline form v of agomelatine, a process for its preparation and pharmaceutical compositions containing it
GEP20094577B (en) New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it
EP1993557A4 (en) Novel EPOPROSTSOLFORMULATION AND METHOD OF MANUFACTURING THEREOF
PL2210872T3 (pl) Nowa postać krystaliczna III agomelatyny, sposób jej wytwarzania i kompozycje farmaceutyczne ją zawierające
WO2007015931A3 (en) Caspase inhibitor prodrugs
WO2008021235A3 (en) Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives
EP4272734A4 (en) SOLID ORAL FORMULATION FOR COLON CLEANSING
HRP20201470T1 (hr) Oblici soli nilotiniba u krutom stanju
WO2005044824A3 (en) Processes for the preparation of highly pure 3-(2-substituted vinyl) cephalosporin
AU2003297367A1 (en) Process for preparing pharmaceutical formulations using supercritical fluids
EP1646640A4 (en) PROCESS FOR PREPARING HIGH-PURITY 1-ANDROSTEN DERIVATIVES
US10201554B2 (en) Esters of 2-deoxy-monosacharides with anti proliferative activity
MY144578A (en) New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
GEP20064009B (en) Cetylpyridinium salt of an anti-inflammatory agent and armaceutical compositions containing it
TW200509889A (en) Aniline derivatives
AR058282A1 (es) Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.

Legal Events

Date Code Title Description
FC Refusal